Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2020 May 1;84(1):114–121. doi: 10.1097/QAI.0000000000002314

Table 1:

Baseline demographic and clinical characteristics of CTAAC cohort

Variable PHIV
(N = 168)		 Controls
(N = 43)		 P
Age in years: mean (SD) 10.80 (0.89) 10.70 (0.99) .49
Gender: male/female 81/87 18/24 .53
Home language: isiXhosa/ Other 150/18 40/2 .24
Years of education: mean (SD) 4.23 (1.11) 4.35 (1.34) .56
Repeated grades: YES/NO 97(58%)/71(42%) 17(39%)/25(61%) .05
hs-CRP 1.52(1.63) 1.14(1.48) .17
ART regimen: first/second/third line 113/44/11
Duration of ART: mean years (SD) 7.08 (2.41)
Age of initiation: mean years (SD) 3.48 (2.52)
Viral load (copies/mL): median(IQR); >50 0(40)
Detectable/Undetectable viral load 30(18%)/138(82%)
CD4 count (cells/mm3): mean (SD) 980 (503)

P values are provided for T tests in the case of interval data, and Chi square in the case of nominal data. hs-CRP= highly sensitive c-reactive protein; ART=antiretroviral therapy. 30 patients have detectable VL, i.e. over 50 copies/mL.